Paxlovid (Nirmatrelvir/Ritonavir) (Paxlovid 150 mg/100 mg Film Kaplı Tablet) and Suvorexant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A inhibitors may slow suvorexant elimination.
Clinical significance and safety
Paxlovid (Nirmatrelvir/Ritonavir) and Suvorexant: Strong CYP3A inhibitors may slow suvorexant elimination. The suvorexant label does not recommend co-treatment with strong CYP3A inhibitors; this differs from its instructions for moderate inhibitors. Changes in exposure can affect tolerability or treatment response. The prescriber must check the exact inhibitor, formulation, dose and timing against the cited product information; doses should not be adjusted without that review. Ask a pharmacist or prescriber to review the full medicine list before adding or changing treatment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.